BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 27532276)

  • 1. Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease.
    Ajmera V; Perito ER; Bass NM; Terrault NA; Yates KP; Gill R; Loomba R; Diehl AM; Aouizerat BE;
    Hepatology; 2017 Jan; 65(1):65-77. PubMed ID: 27532276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease.
    Ozturk O; Colak Y; Senates E; Yilmaz Y; Ulasoglu C; Doganay L; Ozkanli S; Oltulu YM; Coskunpinar E; Tuncer I
    World J Gastroenterol; 2015 Jul; 21(26):8096-102. PubMed ID: 26185381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
    Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
    Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
    Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of nonalcoholic steatohepatitis in NAFLD patients: multicentric study.
    Abdel-Razik A; Mousa N; Shabana W; Refaey M; ElMahdy Y; Elhelaly R; Elzehery R; Zalata K; Arafa M; Elbaz S; Hafez M; Awad M
    Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):e1-9. PubMed ID: 26469357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.
    Bril F; McPhaul MJ; Caulfield MP; Clark VC; Soldevilla-Pico C; Firpi-Morell RJ; Lai J; Shiffman D; Rowland CM; Cusi K
    Diabetes Care; 2020 Feb; 43(2):290-297. PubMed ID: 31604692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
    Younossi ZM; Loomba R; Anstee QM; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Goodman ZD; Chalasani NP; Kowdley KV; George J; Lindor K
    Hepatology; 2018 Jul; 68(1):349-360. PubMed ID: 29222917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lower levels of plasma NT-proBNP are associated with higher prevalence of NASH in patients with biopsy-proven NAFLD.
    Qiao ZP; Zheng KI; Zhu PW; Gao F; Ma HL; Li G; Li YY; Targher G; Byrne CD; Zheng MH
    Nutr Metab Cardiovasc Dis; 2020 Sep; 30(10):1820-1825. PubMed ID: 32636124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic fatty liver disease: biomarkers as diagnostic tools for liver damage assessment in adult patients from Argentina.
    Valva P; Rios D; Casciato P; Gadano A; Galdame O; Mullen E; Bertot G; de Matteo E; Preciado MV
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):637-644. PubMed ID: 29384795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
    Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
    Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Features of nonalcoholic steatohepatitis in severely obese children and adolescents undergoing sleeve gastrectomy.
    Alqahtani A; Elahmedi M; Alswat K; Arafah M; Fagih M; Lee J
    Surg Obes Relat Dis; 2017 Sep; 13(9):1599-1609. PubMed ID: 28600116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver fibrosis markers of nonalcoholic steatohepatitis.
    Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M
    World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ADH1B∗2 Is Associated With Reduced Severity of Nonalcoholic Fatty Liver Disease in Adults, Independent of Alcohol Consumption.
    Vilar-Gomez E; Sookoian S; Pirola CJ; Liang T; Gawrieh S; Cummings O; Liu W; Chalasani NP
    Gastroenterology; 2020 Sep; 159(3):929-943. PubMed ID: 32454036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease.
    Koo BK; Um SH; Seo DS; Joo SK; Bae JM; Park JH; Chang MS; Kim JH; Lee J; Jeong WI; Kim W
    Liver Int; 2018 Apr; 38(4):695-705. PubMed ID: 28898507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Prevalence of Nonalcoholic Fatty Liver Disease in Adolescents Undergoing Bariatric Surgery.
    Xanthakos SA; Jenkins TM; Kleiner DE; Boyce TW; Mourya R; Karns R; Brandt ML; Harmon CM; Helmrath MA; Michalsky MP; Courcoulas AP; Zeller MH; Inge TH;
    Gastroenterology; 2015 Sep; 149(3):623-34.e8. PubMed ID: 26026390
    [TBL] [Abstract][Full Text] [Related]  

  • 18.  Vaspin, resistin, retinol-binding protein-4, interleukin-1α and interleukin-6 in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Polymerou V; Papadimitriou KG; Zavos C; Katsinelos P
    Ann Hepatol; 2016; 15(5):705-14. PubMed ID: 27493109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Cytokines and Liver Histology in Children with Nonalcoholic Fatty Liver Disease.
    Perito ER; Ajmera V; Bass NM; Rosenthal P; Lavine JE; Schwimmer JB; Yates KP; Diehl AM; Molleston JP; Murray KF; Scheimann A; Gill R; Glidden D; Aouizerat B
    Hepatol Commun; 2017 Sep; 1(7):609-622. PubMed ID: 29130075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease.
    Bedossa P; Patel K
    Gastroenterology; 2016 Jun; 150(8):1811-1822.e4. PubMed ID: 27003601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.